Loading
AB
Ambrx Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 Oct 2023.
Ambrx Biopharma, Inc.: what insiders have been doing
This page follows insider dealings at Ambrx Biopharma, Inc. as filed with SEC (Form 4). Ambrx Biopharma, Inc. has had no insider filing for more than a year; the last one goes back to 7 March 2024.
In the same market, recent insider purchases at Relmada Therapeutics, Inc. and Uber Technologies, Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
8
Thresholds
n/a
Buy Volume
€9M
1 ops. · all time
Sell Volume
€583,653
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 7 March 2024
Declarations8 total
22,936 sharesCommon StockSEC:0000950170-24-028182:0
48,202 sharesCommon StockSEC:0000950170-24-028190:0
750,000 shares0Common StockSEC:0000950170-23-069446:0
100,000 shares0Common StockSEC:0000950170-23-069448:0
50,000 shares0Common StockSEC:0000950170-23-069447:0
12,778 shares@ US$9.82100.0% of flowCommon StockSEC:0000950170-23-056944:0
50,012 shares@ US$9.82100.0% of flowCommon StockSEC:0000950170-23-056943:0
1,307,311 shares@ US$6.9911100.0% of flowCommon StockSEC:0000929638-23-002829:0
Canonical exit: 21 Jan 2024 (T+90)
8 of 8 declarations
About Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. is a biopharmaceutical company focused on developing therapies based on modified proteins. It is listed on the XNAS market.
